Assoc. prof. Martina Bago Pilátová, DVM, PhD

Last update: 23. 10. 2023

I. BASIC INFORMATION
I.1 Surname Bago Pilátová
I.2 Name Martina
I.3 Titles Assoc. prof. , DVM, PhD
I.4 Year of birth 1976
I.5 Name of the workplace University of Veterinary Medicine and Pharmacy in Košice, Pavol Jozef Šafárik University in Košice
I.6 Address of the workplace Komenského 73, 041 81 Košice, Slovak Republic
I.7 Position associate professor
I.8 E-mail address martina.pilatova@upjs.sk
I.9 Hyperlink to the entry of a person in the Register of university staff https://www.portalvs.sk/regzam/detail/15102
I.10 Name of the study field in which a person works at the university pharmacy
I.11 ORCID iD 3 https://orcid.org/0000-0002-9592-063X
3 Optional item.

II. HIGHER EDUCATION AND FURTHER QUALIFICATION GROWTH
II.a Name of the university or institution II.b Year II.c Study field and programme
II.1 First degree of higher education
II.2 Second degree of higher education University of Veterinary Medicine in Košice 2001 food hygiene
II.3 Third degree of higher education Pavol Jozef Šafárik University, Faculty of Medicine 2005 pharmacology
II.4 Associate professor Pavol Jozef Šafárik University in Košice, Faculty of Medicine 2012 pharmacology
II.5 Professor
II.6 Doctor of Science (DrSc.)

III. CURRENT AND PREVIOUS EMPLOYMENT
III.a Occupation-position III.b Institution III.c Duration
associate professor Pavol Jozef Šafárik University, Faculty of Medicine, Institute of Pharmacology 2014 up to now
researcher Pavol Jozef Šafárik University, Faculty of Medicine, Institute of Pharmacology 2005 2014

IV. DEVELOPMENT OF PEDAGOGICAL, PROFESSIONAL, LANGUAGE, DIGITAL AND OTHER SKILLS
IV.a Activity description, course name, other IV.b Name of the institution IV.c Year
Food toxicology and food safety ILSI Europe, Wageningen, Netherlands 2009
3rd European course of clinical cytometry ESCCA (European Society for Clinical Cell Analysis - Amsterdam, Nedherlands), Antwerps, Belgium 2007
1st European course of clinical cytometry ESCCA (European Society for Clinical Cell Analysis - Amsterdam, Netherlands), Athens, Greece; Antwerps, Belgium 2005
internship during university studies Cancer Research Centre, Salamanca, Spain 2003
internship during university studies Institute of Virology, University of Veterinary Medicine, Wien, Austria 1998

V. OVERVIEW OF ACTIVITIES WITHIN THE TEACHING CAREER AT THE UNIVERSITY
V.1. Overview of the profile courses taught in the current academic year according to study programmes
V.1.a Name of the profile course V.1.b Study programme V.1.c Degree V.1.d Field of study
Pharmaceutical botanypharmacy (join study programme) full time slovak languagecombined 1st and 2ndpharmacy

V.2. Overview of the responsibility for the delivery, development and quality assurance of the study programme or its part at the university in the current academic year 4
V.2.a Study programme V.2.b Degree V.2.d Field of study
4 According to Art. 6 para. 4 of the Standards for the Study Programme.

V.3. Overview of the responsibility for the development and quality of the field of habilitation procedure and inaugural procedure in the current academic year
V.3.a Name of the field of habilitation procedure and inaugural procedure V.3.b Study field to which it is assigned

V.4. Overview of supervised final theses
V.4.a Bachelor's (first degree) V.4.b Diploma (second degree) V.4.c Dissertation (third degree)
V.4.1 Number of currently supervised theses 0 0 3
V.4.2 Number of defended theses 0 13 5

V.5. Overview of other courses taught in the current academic year according to study programmes
V.5.a Name of the course V.5.b Study programme V.5.c Degree V.5.d Field of study

VI. OVERVIEW OF THE RESEARCH/ARTISTIC/OTHER OUTPUTS
VI.1. Overview of the research/artistic/other outputs and the corresponding citations
VI.1.a Overall VI.1.b Over the last six years
VI.1.1 Number of the research/artictic/other outputs 178 44
VI.1.2 Number of the research/artictic/other outputs registered in the Web of Science or Scopus databases 53 20
VI.1.3 Number of citations corresponding to the research/artictic/other outputs 513 318
VI.1.4 Number of citations registered in the Web of Science or Scopus databases 483 298
VI.1.5 Number of invited lectures at the international, national level 1 1

VI.2. The most significant research/artistic/other outputs 5
1. ADC: Martina Pilátová, Peter Kutschy, Roman Mezencev, Ladislav Mirossay, Andrej Miroššay, Ján Mojžiš, Kenji Monde, Mojmír Suchý, Marek Šarišský, Zuzana Čurillová: Cruciferous phytoalexins: antiproliferative effects in T-Jurkat leukemic cells. Leukemia Research. - Vol. 29, iss. 4 (2005), p. 415-421. 38 x
2. ADC: VAŠKOVÁ J, ČIŽMÁROVÁ B, BAGO PILÁTOVÁ M, KRON I, VAŠKO L: Effects of humic acids in vitro . In Vitro Cellular & Developmental Biology-Animal. 376-382, 2011. (IF=1,665) cit. 53 x
3. ADC: Bago Pilátová M., Varinská L., Perjési P., Šarišský M., Mirossay L., Solár P., Ostró A., Mojžiš J. „In vitro antiproliferative and antiangiogenic effects of synthetic analogues.“ Toxicol. In Vitro, 2010 (24/5), 1347-55. (IF= 2,457 -IF, Q1) cit. 51 x
4. ADD: Mezencev R, Mojžiš J, Pilátová M, Kutschy P: Antiproliferative and cancer chemopreventive activity of phytoalexins. Focus on indole phytoalexins from crucifers. Neoplasma, 239-245, 2003. (IF=1,721) cit. 41 x.
5. ADC: SELIGA R, BAGO PILÁTOVÁ M, ŠARIŠSKÝ M, VÍGLASKÝ V, WALKO M, MOJŽIŠ J: Novel naphthalimide polyamine derivatives as potential antitumor agents . Molecular Biology Reports, 4129-4137, 2013. (IF=2,107) cit. 24 x.
5 Maximum of five most significant outputs, if the RATP form is attached to the application.

VI.3. The most significant research/artistic/other outputs over the last six years 6
1. ADC: Takáč P, Kello M, Bago Pilátová M, Kudličková Z, Vilková M, Slepčíková P, Petik P, Mojžiš J: New chalcone derivative exhibits antiproliferative potential by inducing G2/M cell cycle arrest, mitochondrial-mediated apoptosis and modulation of MAPK signalling pathway. Chemico-Biological Interactions : a Journal of Molecular, Cellular and Biochemical Toxicology, 37-49, 2018 (IF= 3,723; Q1) cit. 22 x
2. ADC: Kello M, Drutovič D, Bago Pilátová M, Tischlerová V, Perjési P, Mojžiš J: Chalcone derivatives cause accumulation of colon cancer cells in the G2/M phase and induce apoptosis. Life Sciences, 32-38, 2016 (IF=3,647; Q1) cit. 23 x
3. ADC: Bogdanová A., Kello M., Macejová A., Nosalová N., Petik P., Takáč P., Martinková M., Mezeiová E., Mirossay L., Gál P., Bago Pilátová M.* „Jaspine B hydrochloride-induced apoptosis in HeLa cells is associated with disrupted shingolipid metabolism and ceramide overload.“ Anticancer Res 2021, 41, 2875-2883 (6), ADC (2020: 2.48 - IF, Q2 - JCR, Q2 - SJR) cit. 1x
4. ADC: Mojžišová G, Kello M, Pilátová M, Tomečková V, Vašková J, Vaško L, Bernatova S, Mirossay L, Mojžiš J: Antiproliferative effect of ß-escin - an in vitro study. Acta Biochimica Polonica, 79-87, 2016 (IF= 1,463; Q1). cit. 16 x.
5. ADC: Špaková Raschmanová, J.; Martinková, M.*; Gonda, J.; Bago Pilátová, M.; Kuchár, J.; Jáger, D. „Synthesis and in vitro biological evaluation of 3-amino-3-deoxydihydrosphingosines and their related analogues“ Tetrahedron 2020, 76, article number 130803, 1‒17. (0), ADC, (2019: 2.235 - IF= 2,235; Q2) cit. 2x
6 Maximum of five most significant outputs over the last six years, if the RATP form is attached to the application.

VI.4. The most significant citations corresponding to the research/artistic/other outputs 7
1. Citovaný dokument: Pilátová M., Šarišský M., Kutschy P., Miroššay A., Mezencev R., Čurillová, Z., Suchý, M., Monde, K., Mirossay, L., Mojžiš J.: Cruciferous phytoalexins: Antiproloferative effects in T-Jurkat leukemic cells. Leuk. Res. 29, 415-421, 2005. (IF=2,636; Q2) cit 38x; Ohlas: ADC: Banerjee, T., DuHadaway, J. B., Gaspari, P., Sutanto-Ward, E., Munn, D. H., Mellor, A. L., Malachowski, W. P., Prendergast, G. C.,(Muller, A. J.: A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene 27, 2851-2857, 2008 (IF=7.55; Q1)
2. Citovaný dokument: Pilátová M., Šarišský M., Kutschy P., Miroššay A., Mezencev R., Čurillová, Z., Suchý, M., Monde, K., Mirossay, L., Mojžiš J.: Cruciferous phytoalexins: Antiproloferative effects in T-Jurkat leukemic cells. Leuk. Res. 29, 415-421, 2005. (IF=2,636; Q2) cit 38x; Ohlas: ADC: Solárová Z, Kello M, Varinská L, Budovská M, Solár P: AInhibition of heat shock protein (Hsp) 90 potentiates the antiproliferative and pro-apoptotic effects of 2-(4'fluorophenylamino)- 4H-1,3-thiazine[6,5-b]indole in A2780cis cells. Biomedicine & Pharmacotherapy, 463-471, 2017 (IF=4,545; Q1)
3. Citovaný dokument: Pilátová M., Šarišský M., Kutschy P., Miroššay A., Mezencev R., Čurillová, Z., Suchý, M., Monde, K., Mirossay, L., Mojžiš J.: Cruciferous phytoalexins: Antiproloferative effects in T-Jurkat leukemic cells. Leuk. Res. 29, 415-421, 2005. (IF=2,636; Q2) cit 36x; Ohlas: ADC: Banerjee, T., DuHadaway, J. B., Gaspari, P., Sutanto-Ward, E., Munn, D. H., Mellor, A. L., Malachowski, W. P., Prendergast, G. C.,Muller, A. J.: A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene 27, 2851-2857, 2008 (IF=7.55; Q1)
4. Citovaný dokument: Pilátová M, Stupáková V, Varinská L, Šarišský M, Mirossay L, Miroššay A, Gál P, Kraus V, Dianišková K, Mojžiš J: Effect of selected flavones on cancer and endothelial cells. General Physiology and Biophysics, 134-143, 2010 (IF=1,192; Q1) cit. 19 x; Ohlas: ADC: Calabriso N , Massaro M, Scoditti E, Pellegrino M, Ingrosso I, Giovinazzo G, Carluccio MA; et al.: Red Grape Skin Polyphenols Blunt Matrix Metalloproteinase-2 and -9 Activity and Expression in Cell Models of Vascular Inflammation: Protective Role in Degenerative and Inflammatory Diseases. Molecules, 1147, 2016 (IF=3,267; Q1)
5. Citovaný dokument: Pilátová M., Šarišský M., Kutschy P., Miroššay A., Mezencev R., Čurillová, Z., Suchý, M., Monde, K., Mirossay, L., Mojžiš J.: Cruciferous phytoalexins: Antiproloferative effects in T-Jurkat leukemic cells. Leuk. Res. 29, 415-421, 2005. (IF=2,636; Q2) cit 38x Ohlas: ADC: Yasuyuki I, Shingo Y, Yoshihiro S, Toshiyuki S: Brassinin induces G1 phase arrest through increase of p21 and p27 by inhibition of the phosphatidylinositol 3-kinase signaling pathway in human colon cancer cells. International Journal of Oncology, 816-824, 2012 (IF=3,899; Q1)
7 Maximum of five most significant citations, if the RATP form is attached to the application.

VI.5. Participation in conducting (leading) the most important research projects or art projects over the last six years 8
1. VEGA 11/0546/16: Antiproliferatívne účinky novonasyntetizovaných analógov jaspínu B a ich vplyv na nádorovú angiogenézu. Zodpovedný riešiteľ: Pilátová, Martina, MVDr. PhD.
2. VEGA 1/0304/10: Antiproliferatívny účinok indolových fytoalexínov a ich syntetických derivátov. Zodpovedný riešiteľ: Pilátová, Martina, MVDr. PhD.
3. VEGA 1/0753/17; Vplyv prírodných látok na nádorové mikroprostredie. Roky realizácie: 2017-2020, Pozícia: zástupca
4. VEGA 1/0322/14: Indolové fytoalexíny - mechanizmus antiproliferatívneho účinku. Roky realizácie: 2014-2016. Zodpovedný riešiteľ: prof. MVDr. J. Mojžiš, CSc.; zástupca ved. projektu: Pilátová, Martina, doc. MVDr. PhD.
5. VEGA 1/0617/22: SLAMF receptory u chronickej lymfocytovej leukémie - potenciálne ciele protinádorovej liečby. Zodpovedný riešiteľ: PharmDr. M. Šarišský, PhD.; zástupca ved. projektu: Bago Pilátová, Martina, doc. MVDr. PhD.
8 Maximum of five most significant projects, if the RATP form is attached to the application. In addition to the name and brief characteristics of the project, the type of participation is indicated (in Slovak and in English), if possible, a hyperlink to the project and its outputs and citations are stated as well.

VII. OVERVIEW OF ORGANIZATIONAL EXPERIENCE RELATED TO HIGHER EDUCATION AND RESEARCH/ARTISTIC/OTHER ACTIVITIES 9
VII.a Activity, position VII.b Name of the institution, board VII.c Duration
9 E.g. academic positions, memberships in editorial boards and in scientific and professional societies.

VIII. OVERVIEW OF INTERNATIONAL MOBILITIES AND VISITS ORIENTED ON EDUCATION AND RESEARCH/ARTISTIC/ OTHER ACTIVITIES IN THE GIVEN FIELD OF STUDY
VIII.a Name of the institution VIII.b Address of the institution VIII.c Duration (indicate the duration of stay) VIII.d Mobility scheme, employment contract, other (describe)
European Society for Clinical Cell Analysis (ESCCA) Amsterdam, Netherlands 2007 2007 3rd European course in clinical cytometry
European Society for Clinical Cell Analysis (ESCCA) Amsterdam, Netherlands 2005 2005 1st European course in clinical cytometry
Cancer Research Centre Salamanca, Spain 2003 2003 Erasmus Fellowship

IX. OTHER RELEVANT FACTS 10
IX.a If relevant, other activities related to higher education or research/artictic/other activities are mentioned
10 Maximum of 1800 characters, if the RATP form is attached to the application.
Skip to content